Akseli Hemminki

28.2k total citations · 3 hit papers
348 papers, 14.9k citations indexed

About

Akseli Hemminki is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Akseli Hemminki has authored 348 papers receiving a total of 14.9k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Oncology, 235 papers in Genetics and 136 papers in Molecular Biology. Recurrent topics in Akseli Hemminki's work include Virus-based gene therapy research (217 papers), CAR-T cell therapy research (164 papers) and Viral Infectious Diseases and Gene Expression in Insects (73 papers). Akseli Hemminki is often cited by papers focused on Virus-based gene therapy research (217 papers), CAR-T cell therapy research (164 papers) and Viral Infectious Diseases and Gene Expression in Insects (73 papers). Akseli Hemminki collaborates with scholars based in Finland, United States and Germany. Akseli Hemminki's co-authors include Kari Hemminki, Anna Kanerva, Jan Sundquist, Matias Riihimäki, Lauri A. Aaltonen, Reijo Salovaara, Vincenzo Cerullo, Kristina Sundquist, Heikki Järvinen and Otto Hemminki and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Nature Genetics.

In The Last Decade

Akseli Hemminki

335 papers receiving 14.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Incidence of Hereditary Nonpolyposis Colorectal Cancer and the Feasibility of Molecular Screening for the Disease

1998 856 citations Lauri A. Aaltonen, Reijo Salovaara et al. profile →
Patterns of metastasis in colon and rectal cancer

2016 650 citations Matias Riihimäki, Akseli Hemminki et al. profile →
Metastatic sites and survival in lung cancer

2014 608 citations Matias Riihimäki, Akseli Hemminki et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Akseli Hemminki Finland	61	8.9k	7.2k	6.3k	2.8k	1.8k	348	14.9k
Nicholas R. Lemoine United Kingdom	73	7.3k 0.8×	3.8k 0.5×	8.7k 1.4×	880 0.3×	1.6k 0.9×	267	16.4k
John Nemunaitis United States	76	13.9k 1.6×	5.2k 0.7×	9.8k 1.6×	995 0.4×	2.0k 1.1×	547	25.4k
Takashi Tokino Japan	62	6.5k 0.7×	1.7k 0.2×	12.8k 2.0×	1.7k 0.6×	1.1k 0.6×	227	17.4k
Igor Puzanov United States	59	10.2k 1.2×	1.9k 0.3×	6.8k 1.1×	1.0k 0.4×	473 0.3×	302	15.5k
Manuel Perucho United States	50	7.1k 0.8×	2.3k 0.3×	7.9k 1.3×	6.6k 2.3×	403 0.2×	140	15.5k
Patrick Hwu United States	53	10.8k 1.2×	2.1k 0.3×	6.6k 1.1×	694 0.2×	858 0.5×	200	17.4k
Stephan A. Grupp United States	74	21.4k 2.4×	6.5k 0.9×	8.2k 1.3×	1.4k 0.5×	381 0.2×	326	29.3k
Thea D. Tlsty United States	50	4.9k 0.5×	1.4k 0.2×	5.7k 0.9×	1.1k 0.4×	657 0.4×	109	10.6k
Richard M. Sherry United States	51	18.5k 2.1×	3.8k 0.5×	6.1k 1.0×	680 0.2×	1.1k 0.6×	97	25.0k
Wyndham H. Wilson United States	66	9.0k 1.0×	1.2k 0.2×	4.0k 0.6×	8.2k 2.9×	687 0.4×	329	17.6k

Countries citing papers authored by Akseli Hemminki

Since Specialization

Citations

This map shows the geographic impact of Akseli Hemminki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akseli Hemminki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akseli Hemminki more than expected).

Fields of papers citing papers by Akseli Hemminki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akseli Hemminki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akseli Hemminki. The network helps show where Akseli Hemminki may publish in the future.

Co-authorship network of co-authors of Akseli Hemminki

This figure shows the co-authorship network connecting the top 25 collaborators of Akseli Hemminki. A scholar is included among the top collaborators of Akseli Hemminki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akseli Hemminki. Akseli Hemminki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.

Quixabeira, Dafne C.A., Susanna Grönberg-Vähä-Koskela, Camilla Heiniö, et al.. (2023). An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage. Frontiers in Immunology. 14. 1171083–1171083. 4 indexed citations

Zafar, Sadia, Dafne C.A. Quixabeira, João M. Santos, et al.. (2020). Oncolytic Adenovirus Type 3 Coding for CD40L Facilitates Dendritic Cell Therapy of Prostate Cancer in Humanized Mice and Patient Samples. Human Gene Therapy. 32(3-4). 192–202. 21 indexed citations

Hekim, Can, Mette Ilander, Jun Yan, et al.. (2017). Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models. Cancer Immunology Research. 5(2). 157–169. 37 indexed citations

Liikanen, Ilkka, Siri Tähtinen, Kilian Guse, et al.. (2016). Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics. 15(9). 2259–2269. 30 indexed citations

Tähtinen, Siri, Susanna Grönberg-Vähä-Koskela, Mikko Siurala, et al.. (2015). Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor. Cancer Immunology Research. 3(8). 915–925. 59 indexed citations

Kanerva, Anna, Petri Nokisalmi, Iulia Diaconu, et al.. (2013). Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research. 19(10). 2734–2744. 144 indexed citations

Koski, Anniina, Eerika Karli, Anja Kipar, et al.. (2013). Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism. PLoS ONE. 8(4). e60032–e60032. 8 indexed citations

Riihimäki, Matias, Hauke Thomsen, Akseli Hemminki, Kristina Sundquist, & Kari Hemminki. (2013). Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 13(1). 36–36. 66 indexed citations

10.

Diaconu, Iulia, Vincenzo Cerullo, Mari Hirvinen, et al.. (2012). Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. Cancer Research. 72(9). 2327–2338. 136 indexed citations

11.

Pesonen, Sari, Iulia Diaconu, Lotta Kangasniemi, et al.. (2012). Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Cancer Research. 72(7). 1621–1631. 107 indexed citations

12.

Guse, Kilian, Masataka Suzuki, Gautam Sule, et al.. (2012). Capsid-Modified Adenoviral Vectors for Improved Muscle-Directed Gene Therapy. Human Gene Therapy. 23(10). 1065–1070. 21 indexed citations

13.

Dias, João D., Ilkka Liikanen, Kilian Guse, et al.. (2010). Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. Clinical Cancer Research. 16(9). 2540–2549. 36 indexed citations

14.

Myllykangas, Liisa, Tiina Paunio, Annukka Marjamaa, et al.. (2010). Ulkomaiset lääkärit, hammaslääkärit ja tieteelliset jatko-opiskelijat Suomessa. 41. 3309–3314.

15.

Hakkarainen, Tanja, Maria Rajecki, Mirkka Sarparanta, et al.. (2009). Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter. Clinical Cancer Research. 15(17). 5396–5403. 33 indexed citations

16.

Strauss, Robert, Pavel Sova, Ying Liu, et al.. (2009). Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic Adenoviruses. Cancer Research. 69(12). 5115–5125. 57 indexed citations

17.

Alhopuro, Pia, Hafid Alazzouzi, Heli Sammalkorpi, et al.. (2005). SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clinical Cancer Research. 11(17). 6311–6316. 74 indexed citations

18.

Hoeben, Rob C., Martijn J. W. E. Rabelink, Leonard I. Wiebe, et al.. (2004). Molecular Imaging and Treatment of Malignant Gliomas Following Adenoviral Transfer of the Herpes Simplex Virus-Thymidine Kinase Gene and the Somatostatin Receptor Subtype 2 Gene. Cancer Biotherapy and Radiopharmaceuticals. 19(1). 111–120. 11 indexed citations

19.

Hemminki, Akseli, Minghui Wang, Tanja Hakkarainen, et al.. (2003). Production of an EGFR targeting molecule from a conditionally replicating adenovirus impairs its oncolytic potential. Cancer Gene Therapy. 10(8). 583–588. 24 indexed citations

20.

Arafat, Waleed, Jesús Gómez-Navarro, Donald J. Buchsbaum, et al.. (2002). Effective single chain antibody (scFv) concentrations in vivo via adenoviral vector mediated expression of secretory scFv. Gene Therapy. 9(4). 256–262. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact